Vault PromoMats

Electronic Certificate

Major Version: 1

Minor Version: 2

Document Number: US-AFR-2328

Document Name: US-AFR-2328_Sample Letter of Appeal

Product: Afrezza

Type: Material

Sub Type: Promotional

Classification: Market Access

Reapproval Count: 3

Certification Statement
We certify that the final electronic form of this material is in accordance with each stated region's regulatory requirements, and is a fair and truthful presentation of the facts about the product.

Role	Signature
Role: Medical Workflow: Reapproval Certification - Medical Outcome: Approved for Continued Use	Name: Medical Affairs (medical-review@mannkindcorp.com) Date: 21-May-2024 17:51:11 GMT+0000 Statement: I hereby certify that "US-AFR-2328_Sample Letter of Appeal" is approved for continued use.

Letter of Appeal for Afrezza® (insulin human) Inhalation Powder

Payer Name: _____
Address: _____
Phone: _____
Fax: _____

RE: Patient Name: _____
Member ID: _____
Policy Group: _____
Date of Birth: _____
(mm/dd/yyyy)

_____
Date

Attn: _____,

I am writing this letter to appeal the denial of coverage for Afrezza® (insulin human) Inhalation Powder on behalf of my patient, _____. Currently, there is not an FDA-approved therapeutic equivalent option available for Afrezza. Afrezza is the **only** ultra rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with type 1 and type 2 diabetes mellitus.[1] Afrezza is the **only** mealtime insulin that mimics the time-action profile of physiologic insulin and offers a needle-free insulin delivery route of administration.[1] Full Prescribing Information for Afrezza can be found at www.afrezza.com.

On _____, your organization cited _____as the reason for denial. However, based on the FDA-approved indication, I strongly believe treatment with Afrezza is medically necessary. Afrezza is medically necessary for _____as documented by:

My Patient, _____, is an appropriate candidate for Afrezza due to the fact that the patient is older than 18, a non-smoker, does not have any chronic lung diseases, and has already performed a recent spirometry (FEV_1) test on _____with a baseline reading of_____. Furthermore, the American Diabetes Association includes data on inhaled insulin in its current Standards of Medical Care in Diabetes, clearly indicating that inhaled insulin has a rapid peak and shortened duration of action compared with RAA and may cause less hypoglycemia and weight gain.[2]

Please call my office at _____if I can provide you with additional information to approve my request. If you have any additional questions regarding this request, please do not hesitate to contact the office. Thank you for your prompt attention to this matter.

Sincerely,

_____

Office Name:

Phone:

References: 1.Afrezza (insulin human) Inhalation Powder Prescribing Information. MannKind Corporation. 2. American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: *Standards of Care in Diabetes*—2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S158–S178.

These pages are for your reference only. Content on the pages below do not need to be sent to the insurance company.

Indications and Usage:
Afrezza® (insulin human) Inhalation Powder is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis, not recommended in patients who smoke or have recently stopped smoking.

Important Safety Information

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE

- **Acute bronchospasms has been observed in AFREZZA-treated patients with asthma and COPD.**
- **AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD.**
- **Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV_1) to identify potential lung disease in all patients.**

Contraindications
AFREZZA is contraindicated: during episodes of hypoglycemia, in patients with chronic lung disease (such as asthma or chronic obstructive pulmonary disease [COPD]) because of the risk of acute bronchospasm, and in patients with hypersensitivity to regular human insulin or any of the excipients in AFREZZA.

Warnings and Precautions
Acute Bronchospasm: In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported. Before initiating therapy, evaluate all patients with a medical history, physical examination, and spirometry (FEV_1) to identify potential underlying lung disease. Do not use in patients with chronic lung disease such as asthma or COPD.

Hypoglycemia or Hyperglycemia with Changes in Insulin Regimen: Glucose monitoring is essential for patients receiving insulin therapy. Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. These changes should be made under close medical supervision and the frequency of blood glucose monitoring should be increased. For patients with type 2 diabetes, dosage modifications of concomitant oral antidiabetic treatment may need to be needed.

Hypoglycemia: Hypoglycemia is the most common adverse reaction associated with insulins, including AFREZZA. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place an individual and others at risk in situations where these abilities are important (e.g., driving or operating other machinery). Hypoglycemia can happen suddenly, and symptoms may differ across patients and change over time in the same patient. Patients and caregivers should be educated to recognize and manage hypoglycemia. Self-monitoring of blood glucose plays an essential role in the prevention and management of hypoglycemia.

Decline in Pulmonary Function: AFREZZA causes a decline in lung pulmonary function over time as measured by FEV_1. In clinical trials excluding patients with chronic lung disease and lasting up to 2 years, AFREZZA-treated patients experienced a small (40 mL) but greater FEV_1 decline than comparator-treated patients. Assess pulmonary function with spirometry at baseline, after the first 6 months of therapy and annually thereafter even in the absence of pulmonary symptoms. In patients who have a decline of ≥20% in FEV_1 from baseline, consider discontinuing AFREZZA. Consider more frequent lung function assessment in patients with pulmonary symptoms, e.g., wheezing, bronchospasm, breathing difficulties, or persistent or recurring cough. If symptoms persist, discontinue AFREZZA.

Lung Cancer: In clinical trials, 2 cases of lung cancer were observed in patients exposed to AFREZZA while no cases were reported for the comparators. In both cases, a prior history of heavy tobacco use was identified as a risk factor for lung cancer. Two additional cases of lung cancer (squamous cell and lung blastoma) were reported in non-smokers exposed to AFREZZA after the trial completion. These data are insufficient to determine whether AFREZZA has an effect on lung or respiratory tract tumors. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk of lung cancer, consider whether the benefits of AFREZZA use outweigh this potential risk.

Diabetic Ketoacidosis (DKA): In clinical trials enrolling patients with type 1 diabetes, diabetic ketoacidosis (DKA) was more common in AFREZZA-treated patients (0.43%; n=13) than in comparator-treated patients (0.14%; n=3). Patients with type 1 diabetes should always use AFREZZA in combination with basal insulin. In patients at risk for DKA, such as those with an acute illness or infection, increase the frequency of glucose monitoring and consider discontinuing AFREZZA and giving insulin using an alternate route of administration.

Hypersensitivity Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including AFREZZA . If hypersensitivity reactions occur, discontinue AFREZZA, treat per standard of care and monitor until symptoms and signs resolve.

Hypokalemia: All insulin products, including AFREZZA, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid Retention and Heart Failure with Concomitant Use of Thiazolidinediones (TZDs): Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of TZDs and insulin. Observe these patients for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the TZD should be considered.

Drug Interactions
Certain drugs may affect glucose metabolism, increasing the risk of hypoglycemia or deceasing or increasing the blood glucose lowering effect of AFREZZA. Dose adjustment and increased frequency of blood glucose monitoring may be required. Co-administration of beta-blockers, clonidine, guanethidine, and reserpine with AFREZZA may reduce the signs and symptoms of hypoglycemia. For full list, see Prescribing Information.

Adverse Reactions
The most common adverse reactions associated with AFREZZA are hypoglycemia, cough, and throat pain or irritation.

To report SUSPECTED ADVERSE REACTIONS, contact MannKind Corporation at 1-877-323-8505 or FDA at www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).

Please See Full Prescribing Information, including BOXED WARNING, Medication Guide and Instructions for Use at Afrezza.com/safety.